Rapport Therapeutics (RAPP) Stock Overview
Operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
RAPP Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.
Read full narrativeRapport Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$39.93 |
| 52 Week High | US$42.27 |
| 52 Week Low | US$7.73 |
| Beta | 0 |
| 1 Month Change | 19.23% |
| 3 Month Change | 47.40% |
| 1 Year Change | 274.93% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 91.97% |
Recent News & Updates
Recent updates
Shareholder Returns
| RAPP | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 20.5% | 6.2% | 3.2% |
| 1Y | 274.9% | 33.4% | 31.0% |
Return vs Industry: RAPP exceeded the US Pharmaceuticals industry which returned 33.4% over the past year.
Return vs Market: RAPP exceeded the US Market which returned 31% over the past year.
Price Volatility
| RAPP volatility | |
|---|---|
| RAPP Average Weekly Movement | 7.8% |
| Pharmaceuticals Industry Average Movement | 9.6% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in US Market | 16.1% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: RAPP has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: RAPP's weekly volatility has decreased from 20% to 8% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2022 | 84 | Abe Ceesay | www.rapportrx.com |
Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. The company’s lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorder. It also develops nicotinic acetylcholine receptor (nAChR) programs, such as a6 nAChR to treat chronic pain and migraine; and a9a10 nAChR for the treatment of hearing/vestibular disorders.
Rapport Therapeutics, Inc. Fundamentals Summary
| RAPP fundamental statistics | |
|---|---|
| Market cap | US$1.77b |
| Earnings (TTM) | -US$107.28m |
| Revenue (TTM) | US$20.00m |
Is RAPP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RAPP income statement (TTM) | |
|---|---|
| Revenue | US$20.00m |
| Cost of Revenue | US$0 |
| Gross Profit | US$20.00m |
| Other Expenses | US$127.28m |
| Earnings | -US$107.28m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.24 |
| Gross Margin | 100.00% |
| Net Profit Margin | -536.39% |
| Debt/Equity Ratio | 0% |
How did RAPP perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/07 20:25 |
| End of Day Share Price | 2026/05/07 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Rapport Therapeutics, Inc. is covered by 12 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kambiz Yazdi | BTIG |
| Jason Butler | Citizens JMP Securities, LLC |
| Salveen Richter | Goldman Sachs |